Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
In development [GID-TA10418] Expected publication date: TBC
Search results
517 results
-
-
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
In development [GID-TA10576] Expected publication date: TBC
-
Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605
In development [GID-TA10488] Expected publication date: TBC
-
Prostate cancer (prevention) - dutasteride [ID75]
In development [GID-TAG409] Expected publication date: TBC
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
In development [GID-TAG411] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455
In development [GID-TA10356] Expected publication date: TBC
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
In development [GID-TAG393] Expected publication date: TBC
-
Hypercholesterolemia - mipomersen [ID524]
In development [GID-TAG437] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
In development [GID-TAG433] Expected publication date: TBC
-
Thrombophilia [ID393]
In development [GID-TAG374] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Falls - faller's clinics [ID103]
In development [GID-TAG375] Expected publication date: TBC
-
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]
In development [GID-TAG436] Expected publication date: TBC
-
Lung cancer (non-small-cell) - cetuximab [ID9]
In development [GID-TAG395] Expected publication date: TBC
-
Venous thromboembolism (prevention) - rivaroxaban [ID463]
In development [GID-TAG427] Expected publication date: TBC
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Heart failure (acute) - serelaxin [ID673]
In development [GID-TAG454] Expected publication date: TBC
-
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
In development [GID-TAG332] Expected publication date: TBC
-
Macular oedema (diabetic) - pegaptanib sodium [ID452]
In development [GID-TAG280] Expected publication date: TBC
-
Venous thromboembolism - apixaban (acute medical illness) [ID310]
In development [GID-TAG419] Expected publication date: TBC
-
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
In development [GID-TAG417] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]
In development [GID-TAG404] Expected publication date: TBC
-
Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]
In development [GID-TAG528] Expected publication date: TBC
-
Juvenile idiopathic arthritis - abatacept [ID27]
In development [GID-TAG402] Expected publication date: TBC
-
Glioblastoma - bevacizumab [ID80]
In development [GID-TAG413] Expected publication date: TBC
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
In development [GID-TAG360] Expected publication date: TBC
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
In development [GID-TAG320] Expected publication date: TBC
-
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
In development [GID-TAG435] Expected publication date: TBC
-
Generalised anxiety disorder - quetiapine [ID347]
In development [GID-TAG421] Expected publication date: TBC
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC
-
Melanoma (advanced and metastatic) - temozolomide [ID316]
In development [GID-TAG401] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
In development [GID-TAG406] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC